Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultevursen versus sham for USH2A exon 13 retinitis pigmentosa
2024-515199-10-01Phase 2Authorised
- Sponsor
- Laboratoires Théa
- Start
- Sep 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) and Usher syndrome type 2A (USH2A) (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Annualized percent change from baseline in ellipsoid zone width. Planned start Sep 2025; status: authorised.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2A (USH2A)
Beyond the preview
Go deeper on 2024-515199-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515199-10-01.